H8-A5

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 561262

CAS#: 423731-10-6

Description: H8-A5 is a novel HDAC8 inhibitor. H8-A5 is selective for HDAC8 over HDAC 1/4 and shows antiproliferation activity in MDA-MB-231 cancer cells.


Price and Availability

Size
Price

Size
Price

Size
Price

H8-A5 is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to sales@medkoo.com to inquire quote.


Chemical Structure

img

Theoretical Analysis

MedKoo Cat#: 561262
Name: H8-A5
CAS#: 423731-10-6
Chemical Formula: C14H9F3N2O2S
Exact Mass: 326.0337
Molecular Weight: 326.29
Elemental Analysis: C, 51.53; H, 2.78; F, 17.47; N, 8.59; O, 9.81; S, 9.83


Synonym: H8-A5; H8A5; H8 A5

IUPAC/Chemical Name: 1-[5-[(1H-Benzimidazol-2-ylthio)methyl]-2-furanyl]-2,2,2-trifluoro-ethanone

InChi Key: LJIAJZCOCKLBGW-UHFFFAOYSA-N

InChi Code: InChI=1S/C14H9F3N2O2S/c15-14(16,17)12(20)11-6-5-8(21-11)7-22-13-18-9-3-1-2-4-10(9)19-13/h1-6H,7H2,(H,18,19)

SMILES Code: FC(F)(F)C(C1=CC=C(CSC2=NC3=CC=CC=C3N2)O1)=O


Technical Data

Appearance:
Solid powder

Purity:
>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility:
Soluble in DMSO

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:
293490


References

1: Hou X, Du J, Liu R, Zhou Y, Li M, Xu W, Fang H. Enhancing the Sensitivity of Pharmacophore-Based Virtual Screening by Incorporating Customized ZBG Features: A Case Study Using Histone Deacetylase 8. J Chem Inf Model. 2015 Apr 27;55(4):861-71. doi: 10.1021/ci500762z. Epub 2015 Mar 16. PubMed PMID: 25757142.